Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications

Overview

Journal Polymers (Basel)

Publisher MDPI

Date 2020 Apr 9

PMID 32260469

Citations 13

Authors

Jason Thomas Duskey

Cecilia Baraldi

Maria Cristina Gamberini

Ilaria Ottonelli

Federica da Ros

Giovanni Tosi

Flavio Forni

Maria Angela Vandelli

Barbara Ruozi

Affiliations

Soon will be listed here.

Abstract

Discovering new materials to aid in the therapeutic delivery of drugs is in high demand. PLGA, a FDA approved polymer, is well known in the literature to form films or nanoparticles that can load, protect, and deliver drug molecules; however, its incompatibility with certain drugs (due to hydrophilicity or charge repulsion interactions) limits its use. Combining PLGA or other polymers such as polycaprolactone with other safe and positively-charged molecules, such as chitosan, has been sought after to make hybrid systems that are more flexible in terms of loading ability, but often the reactions for polymer coupling use harsh conditions, films, unpurified products, or create a single unoptimized product. In this work, we aimed to investigate possible innovative improvements regarding two synthetic procedures. Two methods were attempted and analytically compared using nuclear magnetic resonance (NMR), fourier-transform infrared spectroscopy (FT-IR), and dynamic scanning calorimetry (DSC) to furnish pure, homogenous, and tunable PLGA-chitosan hybrid polymers. These were fully characterized by analytical methods. A series of hybrids was produced that could be used to increase the suitability of PLGA with previously non-compatible drug molecules.

Citing Articles

Antitumoral-Embedded Biopolymeric Spheres for Implantable Devices.

Grumezescu V, Gherasim O, Galateanu B, Hudita A Pharmaceutics. 2024; 16(6).

PMID: 38931875 PMC: 11207774. DOI: 10.3390/pharmaceutics16060754.

PLGA-LEC/F127 hybrid nanoparticles loaded with curcumin and their modulatory effect on monocytes.

Cruz J, Alvarez K, Orozco V, Rojas M, Morales-Luckie R, Giraldo L Nanomedicine (Lond). 2024; 19(15):1407-1423.

PMID: 38920352 PMC: 11382718. DOI: 10.1080/17435889.2024.2357530.

Potential role of Chinese medicine nanoparticles to treat coronary artery disease.

Yang R, Gu Y, Qin J, Liu Q, Liu Q Heliyon. 2023; 9(9):e19766.

PMID: 37809499 PMC: 10559060. DOI: 10.1016/j.heliyon.2023.e19766.

Antibody-Functionalized Polymer Nanoparticles for Targeted Antibiotic Delivery in Models of Pathogenic Bacteria Infecting Human Macrophages.

Miranda Calderon L, Alejo T, Santos S, Mendoza G, Irusta S, Arruebo M ACS Appl Mater Interfaces. 2023; 15(34):40213-40227.

PMID: 37596966 PMC: 10877563. DOI: 10.1021/acsami.3c07367.

Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis.

Bahlool A, Fattah S, OSullivan A, Cavanagh B, MacLoughlin R, Keane J Pharmaceutics. 2022; 14(8).

PMID: 36015371 PMC: 9415714. DOI: 10.3390/pharmaceutics14081745.

References

Simon L, Stout R, Sabliov C . Bioavailability of Orally Delivered Alpha-Tocopherol by Poly(Lactic-Co-Glycolic) Acid (PLGA) Nanoparticles and Chitosan Covered PLGA Nanoparticles in F344 Rats. Nanobiomedicine (Rij). 2018; 3:8. PMC: 5998269. DOI: 10.5772/63305. View

Rigon L, Salvalaio M, Pederzoli F, Legnini E, Duskey J, DAvanzo F . Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. Int J Mol Sci. 2019; 20(8). PMC: 6514713. DOI: 10.3390/ijms20082014. View

Nafee N, Taetz S, Schneider M, Schaefer U, Lehr C . Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007; 3(3):173-83. DOI: 10.1016/j.nano.2007.03.006. View

Li X, Jiang X . Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles. Adv Drug Deliv Rev. 2017; 128:101-114. DOI: 10.1016/j.addr.2017.12.015. View

Tosi G, Pederzoli F, Belletti D, Vandelli M, Forni F, Duskey J . Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy. Prog Brain Res. 2019; 245:57-88. DOI: 10.1016/bs.pbr.2019.03.001. View

Thakur C, Thotakura N, Kumar R, Kumar P, Singh B, Chitkara D . Chitosan-modified PLGA polymeric nanocarriers with better delivery potential for tamoxifen. Int J Biol Macromol. 2016; 93(Pt A):381-389. DOI: 10.1016/j.ijbiomac.2016.08.080. View

Rezvantalab S, Drude N, Moraveji M, Guvener N, Koons E, Shi Y . PLGA-Based Nanoparticles in Cancer Treatment. Front Pharmacol. 2018; 9:1260. PMC: 6224484. DOI: 10.3389/fphar.2018.01260. View

Pederzoli F, Ruozi B, Duskey J, Hagmeyer S, Sauer A, Grabrucker S . Nanomedicine Against Aβ Aggregation by β-Sheet Breaker Peptide Delivery: In Vitro Evidence. Pharmaceutics. 2019; 11(11). PMC: 6920811. DOI: 10.3390/pharmaceutics11110572. View

Tosi G, Duskey J, Kreuter J . Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin Drug Deliv. 2019; 17(1):23-32. DOI: 10.1080/17425247.2020.1698544. View

10.

Li A, Sun Z, Zhou M, Xu X, Ma J, Zheng W . Electrospun Chitosan-graft-PLGA nanofibres with significantly enhanced hydrophilicity and improved mechanical property. Colloids Surf B Biointerfaces. 2012; 102:674-81. DOI: 10.1016/j.colsurfb.2012.09.035. View

11.

Li J, Crowley S, Duskey J, Khargharia S, Wu M, Rice K . Miniaturization of gene transfection assays in 384- and 1536-well microplates. Anal Biochem. 2014; 470:14-21. PMC: 4601643. DOI: 10.1016/j.ab.2014.10.001. View

12.

Heux L, Brugnerotto J, Desbrieres J, Versali M, Rinaudo M . Solid state NMR for determination of degree of acetylation of chitin and chitosan. Biomacromolecules. 2001; 1(4):746-51. DOI: 10.1021/bm000070y. View

13.

Cai G, Jiang H, Tu K, Wang L, Zhu K . A facile route for regioselective conjugation of organo-soluble polymers onto chitosan. Macromol Biosci. 2008; 9(3):256-61. DOI: 10.1002/mabi.200800153. View

14.

Najer A, Thamboo S, Duskey J, Palivan C, Beck H, Meier W . Analysis of Molecular Parameters Determining the Antimalarial Activity of Polymer-Based Nanomimics. Macromol Rapid Commun. 2018; 36(21):1923-1928. DOI: 10.1002/marc.201500267. View

15.

Baig M, Ahmad K, Roy S, Ashraf J, Adil M, Siddiqui M . Computer Aided Drug Design: Success and Limitations. Curr Pharm Des. 2015; 22(5):572-81. DOI: 10.2174/1381612822666151125000550. View

16.

Ma F, Li J, Kong M, Liu Y, An Y, Chen X . Preparation and hydrolytic erosion of differently structured PLGA nanoparticles with chitosan modification. Int J Biol Macromol. 2012; 54:174-9. DOI: 10.1016/j.ijbiomac.2012.12.019. View

17.

Chung Y, Kim J, Kim Y, Tae G, Lee S, Kim K . The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. J Control Release. 2010; 143(3):374-82. DOI: 10.1016/j.jconrel.2010.01.017. View

18.

Chakravarthi S, Robinson D . Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm. 2011; 409(1-2):111-20. DOI: 10.1016/j.ijpharm.2011.02.034. View

19.

Tantra R, Oksel C, Puzyn T, Wang J, Robinson K, Wang X . Nano(Q)SAR: Challenges, pitfalls and perspectives. Nanotoxicology. 2014; 9(5):636-42. DOI: 10.3109/17435390.2014.952698. View

20.

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View